Literature DB >> 25488052

The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.

Binnur Önal1, Ünsal Han, Sinasi Yilmaz, Fulya Köybasioglu, Uğur Altuğ.   

Abstract

BACKGROUND: This prospective study compares urine NMP22 immunoassay and cytomorphology for detecting recurrent urothelial carcinoma (UC) of the bladder and correlates between NMP22 levels and grade, multiplicity, and size of the tumor. We aimed refining the use of NMP22 test in the management of UC at our institution.
METHODS: Urine specimens, collected prior to a cystoscopic biopsy either from patients with a history of bladder cancer (n = 50) or from controls (n = 15) were studied. Cytology and NMP22 results were compared with subsequent biopsies and performance characteristics were measured.
RESULTS: Overall sensitivity and specificity of cytology was 62.5% and 87.5%, respectively while NMP22 had a sensitivity of 85.4% and specificity of 76.5%. NMP22 was superior to cytology for detecting low-grade UC (82.6% vs. 54.5%) and in terms of NPV (65% vs. 44.4%) while cytology reached 100% detection rate for high-grade UC. And, the sensitivity of 98% was achieved when NMP22 was combined with atypical cytology. Optimal performance of NMP22 has been detected around the reference value of 6.4 U/ml. The mean NMP22 values in control and study groups were 2.5 U/ml and 36 U/ml, respectively. The mean NMP22 value was 20.9 U/ml in low-grade UC and 53.2 U/ml in high-grade category.
CONCLUSIONS: The NMP22 values displayed higher sensitivity for low-grade UC while cytology was highly sensitive and spesific in detection of high-grade UC. Combining urine NMP22 assay with atypical cytology improved sensitivity for detection of recurrent UC. The inclusion of the adjunctive NMP22 test in monitoring protocols for low-grade UC in combination with cytology for high-grade UC could enable clinicians to decrease the frequency of follow-up cystoscopies.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  NMP22; performance; recurrence; urine cytology; urothelial carcinoma bladder

Mesh:

Substances:

Year:  2014        PMID: 25488052     DOI: 10.1002/dc.23239

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  9 in total

1.  Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study.

Authors:  Michael D Bell; Faysal A Yafi; Fadi Brimo; Jordan Steinberg; Armen G Aprikian; Simon Tanguay; Wassim Kassouf
Journal:  World J Urol       Date:  2016-02-23       Impact factor: 4.226

Review 2.  Bladder cancer detection in patients with neurogenic bladder: are cystoscopy and cytology effective, and are biomarkers pertinent as future diagnostic tools? A scoping review.

Authors:  Marc Sbizzera; Françoise Descotes; Théo Arber; Paul Neuville; Alain Ruffion
Journal:  World J Urol       Date:  2022-02-04       Impact factor: 3.661

3.  Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer.

Authors:  Ekaterina Olkhov-Mitsel; Andrea J Savio; Ken J Kron; Vaijayanti V Pethe; Thomas Hermanns; Neil E Fleshner; Bas W van Rhijn; Theodorus H van der Kwast; Alexandre R Zlotta; Bharati Bapat
Journal:  Transl Oncol       Date:  2017-02-03       Impact factor: 4.243

4.  Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-Muscle Invasive Bladder Cancer in the Han Chinese Population.

Authors:  Zhiyong Wang; Wansheng Gao; Jian Li; Tianen Wang; Man Zhu; Yu Duan
Journal:  J Cancer       Date:  2020-01-14       Impact factor: 4.207

5.  Super-Enhancer LncRNA LINC00162 Promotes Progression of Bladder Cancer.

Authors:  Xin Wang; Ruirui Zhang; Shuilian Wu; Liping Shen; Meixia Ke; Yan Ouyang; Mengqi Lin; Yiting Lyu; Binuo Sun; Zhijian Zheng; Jialei Yang; Jie Yang; Wenmin Lu; Yiping Yang; Danni Li; Yunfeng Zou; Haishan Huang; Aruo Nan
Journal:  iScience       Date:  2020-11-24

6.  Exosome-Derived Long Non-Coding RNAs as Non-Invasive Biomarkers of Bladder Cancer.

Authors:  Quanxin Su; Hao Wu; Ziyi Zhang; Chao Lu; Lifeng Zhang; Li Zuo
Journal:  Front Oncol       Date:  2021-08-19       Impact factor: 6.244

Review 7.  An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.

Authors:  Francesco Soria; Michael J Droller; Yair Lotan; Paolo Gontero; David D'Andrea; Kilian M Gust; Morgan Rouprêt; Marek Babjuk; Joan Palou; Shahrokh F Shariat
Journal:  World J Urol       Date:  2018-06-21       Impact factor: 4.226

8.  Circular RNA circGLIS3 promotes bladder cancer proliferation via the miR-1273f/SKP1/Cyclin D1 axis.

Authors:  Shuilian Wu; Jialei Yang; Haotian Xu; Xin Wang; Ruirui Zhang; Wenmin Lu; Jie Yang; Xiaofei Li; Sixian Chen; Yunfeng Zou; Aruo Nan
Journal:  Cell Biol Toxicol       Date:  2021-03-03       Impact factor: 6.691

Review 9.  Diagnostic performance of nuclear matrix protein 22 and urine cytology for bladder cancer: A meta-analysis.

Authors:  Jie Wang; Xi Zhao; Xiao Lei Jiang; Dong Lu; Qiang Yuan; Jiabing Li
Journal:  Diagn Cytopathol       Date:  2022-03-24       Impact factor: 1.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.